Arsenol (arsenic trioxide oral) / SDK Therapeutics - LARVOL DELTA

A RANDOMIZED, OPEN LABEL, SINGLE-DOSE, 4-PERIOD, 4-TREATMENT CROSS-OVER STUDY TO EVALUATE THE PHARMACOKINETICS OF ORAL ARSENIC TRIOXIDE SOLUTION (SDK001) AND TO COMPARE TO INTRAVENOUS ARSENIC TRIOXIDE (EHA 2025) - "Approximately 12 patients will be enrolled in this study and randomized in a 1:1:1:1 ratio to one of the four treatment sequences with a 7-day washout between periods (Table 1). The primary end-points include: AUCinf of AsIII for the comparison of SDK001 versus i.v.-ATO under fasted condition; Cmax and AUCinf of AsIII, for the comparison of SDK001 under fasted condition versus fed condition; Cmax and AUCinf of AsIII, for the comparison of SDK001 with or without calcium product under fasted state.Table 1 Sequence 1 2 3 4 N 3 3 3 3 Period 1 A B C D Period 2 B D A C Period 3 C A D B Period 4 D C B A A: 0.15 mg/kg i.v.-ATO, fasted; B: 0.15 mg/kg SDK001 fasted; C: 0.15 mg/kg SDK001 fed; D: 0.15 mg/kg SDK001 with 1 g calcium carbonate tablet, fasted."

Clinical • PK/PD data • Acute Myelogenous Leukemia • Acute Promyelocytic Leukemia • Cardiovascular • CNS Disorders • Congestive Heart Failure • Heart Failure • Hematological Malignancies • Leukemia • Oncology • PML

Microstructure and Thermophysical Characterization of Tetra-Arsenic Biselenide As4Se2 Alloy Nanostructured by Mechanical Milling. (PubMed, Materials (Basel)) - "The nanomilled alloys become notably stressed owing to the destruction of molecular thioarsenide and incorporation of their remnants into the newly polymerized arsenoselenide network. This effect is more pronounced in As4Se2 alloy subjected to dry nanomilling, while it is partly counterbalanced when this alloy is additionally subjected to wet milling in a PVP water solution, accompanied by the stabilization of the As4Se2/PVP nanocomposite."

Journal

Oral-ATO for TP53-mutated Myeloid Malignancies (clinicaltrials.gov) - P2 | N=30 | Recruiting | Sponsor: The University of Hong Kong | Not yet recruiting ➔ Recruiting

Enrollment open • Acute Myelogenous Leukemia • Chronic Myelomonocytic Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology

Biodegradation of Arsenosugars from Red Alga Pyropia haitanensis. (PubMed, Environ Sci Technol) - "C71 efficiently transformed phosphate arsenosugar to glycerol arsenosugar extracellularly and intracellularly. This study offers new insights into the interaction between bacteria and organoarsenical degradation, contributing to our understanding of arsenic biogeochemical cycles in marine systems."

Journal

How does the coupled action of freeze-thaw and acidification affect the release of toxic elements from indigenous Zn smelting slags? (PubMed, J Environ Sci (China)) - "More importantly, the geochemical modeling results suggested that the precipitation of hematite and magnetite, as well as the dissolution of arsenolite, might have little impacts on PTEs release under FTs and FTs with acidification. This work would provide a deeper understanding of PTEs release from smelting waste slags under complex physicochemical interactions."

Journal

Evaluate the Pharmacokinetics of Oral Arsenic Trioxide Solution Under Fasting and Fed Conditions, to Compare Intravenous Arsenic Trioxide, in Acute Promyelocytic Leukemia (clinicaltrials.gov) - P1/2 | N=12 | Recruiting | Sponsor: SDK Therapeutics, Inc.

New P1/2 trial • Acute Promyelocytic Leukemia • Hematological Malignancies • Leukemia • Oncology

Arsenolipid-Induced Reproductive Toxicity in Caenorhabditis elegans: Elucidating the Mechanism through the HUS-1-CEP-1-EGL-1-CED-9-CED-4-CED-3 Signaling Pathway. (PubMed, Food Chem Toxicol) - "In addition, the mechanism of arsenolipid-induced nematode reproductive toxicity was further elucidated through the HUS-1-CEP-1-EGL-1-CED-9-CED-4-CED-3 signaling pathway. Therefore, our results suggest that AsHC 332 is more exposed to reproductive toxicity than AsHC 346 and AsHC 360, which is related to changes in physicochemical properties and DNA damage-induced germ cell apoptosis."

Journal • APAF1 • GAS1 • SOD3

Orphan Designation: treatment of acute promyelocytic leukemia (FDA) - Date Designated: 11/19/2024

Orphan drug • Acute Promyelocytic Leukemia